ClinicalTrials.gg
RecruitingNCT07322640Updated Feb 5, 2026

Play Therapy With Gamified Biofeedback in Children With Autism Spectrum Disorder

An interventional study of Gamified Biofeedback and Play Therapy in Autism Spectrum Disorder, sponsored by Luiz Alexandre Viana Magno. Recruiting at 1 site in Brazil. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Luiz Alexandre Viana Magno · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Autism Spectrum Disorder with a site in Brazil — 3 open to participants now, 3 under way, none of them phase 3. Autism Spectrum Disorder · Brazil.

Planned enrollment
5th of 10
68 · median 68
Started
2026
the only one that year
No phase
6 of 11
3 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Luiz Alexandre Viana Magno

Among the 11 studies in Autism Spectrum Disorder with a site in Brazil, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 11th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

3 of the 11 studies in Autism Spectrum Disorder with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Autism Spectrum Disorder with a site in Brazil, or all of them as a file.
02

Study summary

This clinical trial tests whether combining regular play therapy with gamified biofeedback helps children with autism spectrum disorder better regulate their emotions and improve social skills, compared to play therapy alone. Sixty-eight children will be randomly assigned to 8 weekly 50-minute sessions: one group receives play therapy only, while the other receives play therapy plus real-time biofeedback using a comfortable armband that turns heart-rate calming into fun game rewards. Parents and teachers will complete short questionnaires before and after the study. All activities are playful, safe, and designed to feel natural and enjoyable for children with autism.

Read the detailed description

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by persistent difficulties in social communication and interaction, restricted interests, and repetitive behaviors. Even in children with ASD level 1 (requiring support) who have normal or high cognitive abilities, emotional dysregulation is one of the most significant and persistent challenges. These children frequently experience intense physiological arousal in response to everyday sensory or social stimuli, yet they struggle to recognize, interpret, and self-regulate their emotional states. Traditional behavioral and developmental therapies improve communication and reduce repetitive behaviors, but emotional dysregulation often remains a major barrier to social participation, learning, and family well-being, contributing to frequent anxiety, and long-term mental health risks.

This single-center, pragmatic, parallel-group, single-blind (outcome assessor) randomized clinical trial aims to determine whether integrating real-time gamified biofeedback with standard child-centered play therapy produces greater improvements in emotional regulation and socioemotional skills than play therapy alone in children aged 6-10 years diagnosed with ASD level 1 according to DSM-5 criteria.

A total of 68 children will be consecutively recruited from the outpatient clinic of the Faculdade de Ciências Médicas de Minas Gerais (FCMMG), Belo Horizonte, Brazil. After obtaining written informed consent from parents/legal guardians and child assent, participants will be randomly allocated in a 1:1 ratio (using computer-generated randomization) to one of two interventions delivered over 12 weeks in weekly 50-minute individual sessions conducted by the same psychologist experienced in autism spectrum disorder.

Both groups receive identical child-centered play therapy focused on fostering joint attention, symbolic play, reciprocal interaction, and emotional co-regulation in a sensory-friendly room adapted for children with autism. The experimental group additionally receives gamified biofeedback (heart-rate monitor armband that adjusts game difficulty based on arousal level, rewarding successful calming strategies) and continuous physiological monitoring with the a FDA-cleared research device recording heart-rate variability, electrodermal activity, peripheral skin temperature, accelerometry, and respiratory rate). The control group plays the same tablet games but with the biofeedback function deactivated (sham condition).

Blinded assessments are conducted at baseline and immediately after the intervention. The primary outcome is the change in emotion regulation scores. Secondary outcomes include changes in sociability, behavior, parenting stress, and exploratory correlations between physiological biomarkers and clinical improvements. The study follows CONSORT guidelines and has been approved by the institutional ethics committee (CEP-FCMMG).

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • autism spectrum disorder
  • play therapy
  • biofeedback
  • emotional regulation
  • heart rate variability
  • Wearable Electronic Devices
  • children
04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 6 years and 10 years
  • Formal diagnosis of autism spectrum disorder (ASD) level 1 according to criteria, documented by a qualified professional
  • Signed by parent/legal guardian and child assent

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric comorbidities (e.g., psychosis, severe obsessive-compulsive disorder)
  • Uncontrolled epilepsy or to biofeedback procedures
  • Severe intellectual disability that prevents interaction with tablet-based games or biofeedback
  • Severe or decompensated systemic medical conditions (e.g., active cancer, uncontrolled cardiac disease, uncontrolled diabetes)
  • Change in dose or initiation of any psychotropic medication within 4 weeks prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Play Therapy + Gamified Biofeedback

    Children receive 8 weekly 50-minute individual sessions consisting of 35 minutes of child-centered play therapy followed by 15 minutes of gamified biofeedback using a heart-rate armband that adjusts game difficulty in real time plus continuous physiological monitoring with a wristband (HRV, EDA, skin temperature, accelerometry, respiratory rate). The biofeedback games become easier when the child successfully uses calming strategies.

    Behavioral: Gamified Biofeedback · Behavioral: Play Therapy

  • Active comparator
    Play Therapy Alone

    Children receive 8 weekly 50-minute individual sessions identical in structure and duration to the experimental arm (35 minutes of child-centered play therapy). During the final 15 minutes they play the same tablet-based games as the experimental group, but with the biofeedback function deactivated and wearing the devices only for equivalence of contact; no real-time physiological feedback is provided.

    Behavioral: Play Therapy · Behavioral: Deactivated Biofeedback

Interventions

  • BehavioralGamified Biofeedback

    Participants receive 8 weekly 15-minute of gamified biofeedback using a non-invasive heart-rate monitor armband connected to a tablet-based platform. The games increase in difficulty when heart rate rises (indicating emotional arousal) and become easier when the child successfully applies calming strategies such as slow breathing or brief pauses. A second wearable wristband continuously records heart-rate variability, electrodermal activity, peripheral skin temperature, accelerometry, and respiratory rate for objective physiological monitoring throughout the biofeedback segment.

  • BehavioralPlay Therapy

    Participants receive 8 weekly 50-minute individual sessions with therapist of a play-based approach aimed at promoting joint attention, shared engagement, symbolic play, and emotional self-regulation. Toys will be selected according to the child's individual interests and tailored to their level of play development, incorporating both already mastered skills and emerging skills. Within these routines, strategies will be implemented such as: intentional pauses to encourage communicative initiation; expansion of play narratives to increase complexity and flexibility; balanced turn-taking to reinforce social reciprocity; modeling and positive reinforcement of gestures and verbal/nonverbal communication; and integration of emotional regulation techniques within the play context, facilitating the generalization of these skills to other environments.

  • BehavioralDeactivated Biofeedback

    Children will engage in the interactive play-based games used in the active biofeedback condition. The biofeedback device will be installed and worn. However, the biofeedback functionality will be deactivated and no physiological feedback will be provided to or influence the child during gameplay.

06

What researchers measure

Primary outcomes

  1. Change in Emotion Regulation Checklist (ERC) total score

    Parent-rated emotional regulation measured by the Brazilian version of the Emotion Regulation Checklist (ERC). The ERC comprises the scales of Emotion Regulation (Range 8 to 32) andf Emotional Lability/Negativity (Range 15 to 60). An adaptive emotion regulation total score (range 23 to 92) is presented where a higher score is indicative of good emotion regulation and lower scores indicative of poor emotion regulation. This score is calculated by the sum of the emotion regulation scale and the inverse of the emotional lability/negativity scale.

    Time frame: Baseline and 8 weeks of intervention

Secondary outcomes

  1. Change in Social Responsiveness Scale (SRS-2) (parent form)

    Parent-reported Brazilian version of the Social Responsiveness Scale, Second Edition (SRS-2), Parent Form, which assesses the severity of social impairment associated with autism spectrum symptoms. All items are rated on a 4-point Likert scale anchored by not true and almost always true, where high scores indicate greater dysfunction. Raw scores are converted into T-scores for interpretation.

    Time frame: Baseline and 8 weeks of intervention

  2. Change in Social Responsiveness Scale (SRS-2) (teacher form)

    Teacher-reported scores in the Social Responsiveness Scale, Second Edition (SRS-2), Teacher Form, which measures social functioning in the school context. All items are rated on a 4-point Likert scale anchored by not true and almost always true, where high scores indicate greater dysfunction. Raw scores are converted into T-scores for interpretation.

    Time frame: Baseline and 8 weeks of intervention

  3. Change in Child Behavior Checklist (CBCL 6/18)

    Parent-reported Brazilian version of Child Behavior Checklist (CBCL 6/18) is a caregiver-reported measure designed to assess behavioural and emotional problems in children and young people aged 6-18 years. The study will measure the problem behaviour scale, wich contains eight subscales that can be grouped into two higher-order factors, known as the internalising and externalising behaviours. By summing up all the problem items, a Total Problems score can also be computed. Higher scores indicate greater problems.

    Time frame: Baseline and 8 weeks of intervention

  4. Change in Parenting Stress Index (PSI-4 SF)

    The Parenting Stress Index-Fourth Edition, Short Form (PSI-4 SF) assesses overall parenting stress. The total score ranges from 36 to 180, with higher scores indicating greater parenting stress (worse outcome).

    Time frame: Baseline and 8 weeks of intervention

Other outcomes

  1. Correlation between physiological parameters and changes in clinical scales

    hysiological data will be collected during each intervention session, including heart rate variability (HRV), electrodermal activity (EDA), and skin temperature. These measures will be used to characterize session-by-session patterns and within-week changes in autonomic regulation from baseline through the end of the 8-week intervention period. Outcomes will reflect temporal trends and variability in physiological responses across sessions rather than a single summary score.

    Time frame: Session-by-session physiological patterns across the intervention period (Baseline through Week 8)

07

Study locations

1 of 1 sites recruiting
  • Ambulatório da Faculdade de Ciências Médicas de Minas Gerais
    Belo Horizonte, Minas Gerais 30130-110, Brazil
    Recruiting
    • Stela P Chagas, Psychologist · Contactstelapereirachagas@gmail.com · +553132487100
    • Luiz Alexandre V Magno, PhD · Contact
    • Luiz Alexandre V Magno, PhD · Principal investigator
    • Stela P Chagas, Psychologist · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (including data dictionaries) that underlie the results reported in the primary publication (including the primary and secondary outcome measures, baseline characteristics, and adverse events) will be made available upon reasonable request beginning 6 months and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal and have appropriate ethical approval. Requests should be directed to the Principal Investigator.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 6 months after publication - 5 years after publication

Access criteria: Researchers must submit a brief research proposal and sign a data access agreement. Data will be shared via secure file transfer after approval by the Principal Investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 10 months is below that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Jan 7, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07322640
Lead sponsor
Luiz Alexandre Viana Magno
Responsible party
Luiz Alexandre Viana Magno (Principal Investigator, Faculdade de Ciências Médicas de Minas Gerais) — Sponsor-investigator
First posted
Jan 7, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Luiz Alexandre V Magno, PhD
Contact
luiz.magno@cienciasmedicasmg.edu.br
+553132487100
Stela P Chagas, Psychologist
Contact
stelapereirachagas@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion